Zoetis
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its c...
Latest News
14 hours ago · seekingalpha.com
Zoetis Inc. (ZTS) Presents at Jefferies Global Healthcare Conference 2026 TranscriptZoetis Inc. (ZTS) Presents at Jefferies Global Healthcare Conference 2026 Transcript
4 days ago · zacks.com
Zoetis' Cytopoint Plus Gets USDA License for 75-Day Canine Itch ReliefZTS' Cytopoint Plus secures a USDA license, offering dogs with allergic dermatitis 75 days of itch relief and a longer interval between injections.
5 days ago · businesswire.com
Zoetis Receives USDA License for Cytopoint Plus™: The First and Only Long-Acting Monoclonal Antibody Providing 75 Days of Allergic Itch Relief in Dogs with Allergic DermatitisPARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Cytopoint Plus is the first and only USDA-licensed next-generation mAb that provides 75 days of allergic itch relief in a single injection.
6 days ago · businesswire.com
Zoetis to Participate in the Jefferies Global Healthcare Conference in LondonPARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced that Jay Saccaro, EVP, Chief Financial Officer and Chief Operating Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Monday, November 16, 2026 at 2 p.m. GMT. Interested parties can access the live webcast of the presentation by visiting https://investor.zoetis.com/events-presentations. A replay will also be available on the Zoetis website at the conclusion of the event.
8 days ago · zacks.com
ZTS Q3 Earnings Call Highlights Competitive Pressures and OutlookZoetis beats Q3 earnings estimates despite revenue weakness, as competitive pressures, targeted promotions and product innovation shape its cautious 2027 outlook.
8 days ago · marketbeat.com
What Zoetis (ZTS) Said on Its Q3 Earnings CallZoetis NYSE: ZTS reported lower third-quarter revenue as competition and weaker veterinary visits pressured its companion animal business, while livestock and diagnostics provided growth. The animal health company narrowed its full-year revenue outlook to the high end of its previous range and raised its adjusted earnings guidance.
11 days ago · seekingalpha.com
Zoetis: Quality Company Trading CheapZoetis Inc., formerly Pfizer's veterinary arm, is a global leader in animal pharmaceuticals and diagnostics. ZTS generates most revenue from companion animal products, with approximately 30% from livestock healthcare solutions. We review why the stock has done so poorly and tell you why we went long.
11 days ago · seekingalpha.com
Zoetis Inc. (ZTS) Q3 2026 Earnings Call TranscriptZoetis Inc. ( ZTS ) Q3 2026 Earnings Call November 5, 2026 8:30 AM EST Company Participants Mathieu Aussermeier Kristin Peck - CEO & Director James Saccaro - Executive VP, CFO & COO Conference Call Participants Christopher Schott - JPMorgan Chase & Co, Research Division David Westenberg - Piper Sandler & Co., Research Division Jonathan Block - Stifel, Nicolaus & Company, Incorporated, Research Division Brandon Vazquez - William Blair & Company L.L.C., Research Division Erin Wilson Wright - Morgan Stanley, Research Division Matthew Dellatorre - Goldman Sachs Group, Inc., Research Division Navann Ty Dietschi - BNP Paribas, Research Division Christopher LoBianco - TD Cowen, Research Division Andrea Zayco Narvaez Alfonso - UBS Investment Bank, Research Division Steven Dechert - KeyBanc Capital Markets Inc., Research Division Presentation Operator Welcome to the third quarter 2026 financial results conference call and webcast for Zoetis.
11 days ago · fool.com
Zoetis: 3 Key Takeaways for Long-Term InvestorsZoetis's organic operational revenue fell 1% in the third quarter. Global livestock revenue rose 7% to $797 million.
11 days ago · zacks.com
ZTS Q3 Earnings Top Estimates, 2026 Profit Outlook Improves, Stock UpZoetis beats third-quarter earnings and revenue estimates. Livestock sales growth partially offsets weakness in companion animal products.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove ZTS